Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Dec 19;32(1):44.
doi: 10.1007/s00520-023-08235-y.

A randomised trial of topical polaprezinc to prevent oral mucositis in patients undergoing haematopoietic stem cell transplantation (ToPaZ study)

Midori Nakagaki  1   2 , Glen A Kennedy  3   4 , Nicole C Gavin  3   4   5   6 , Jason Butler  3 , Alexandra Clavarino  7 , Karen Whitfield  8
Affiliations
Randomized Controlled Trial

A randomised trial of topical polaprezinc to prevent oral mucositis in patients undergoing haematopoietic stem cell transplantation (ToPaZ study)

Midori Nakagaki et al. Support Care Cancer. .

Abstract

Purpose: Oral mucositis (OM) is a common complication in haematopoietic stem cell transplantation (HSCT). Polaprezinc, an anti-ulcer drug, has been shown to be effective to prevent OM in several studies when administered topically and systemically. This study aimed to evaluate the effectiveness of topical polaprezinc in patients undergoing HSCT.

Methods: This was an open-label randomised clinical trial comparing polaprezinc and sodium bicarbonate mouthwashes for the prevention of severe OM in HSCT patients. Adult patients who received conditioning regimens at moderate to high risk of developing OM were included. The primary endpoint was the incidence of severe (WHO grades 3-4) OM. The secondary endpoints included duration of grades 3-4 OM, incidence and duration of grades 2-4 OM, patient-reported pain and functional limitations.

Results: In total, 108 patients (55 test arm and 53 control arm) were randomised. There was no difference in the incidence of grades 3 to 4 OM (35% test arm versus 36% control arm). The secondary endpoints were not significantly different. In both arms, patients reported more throat pain compared to mouth pain.

Conclusions: Topical polaprezinc had no effect in the prevention of OM in HSCT patients. Further research is required to evaluate the effects of systemic polaprezinc. The OM assessment tool needs to be reviewed as throat mucositis was a main issue in this study.

Trial registration: ACTRN12320001188921 (Date Registered: 10th November 2020).

Keywords: Haematopoietic stem cell transplantation; Oral mucositis; Polaprezinc; Zinc L-carnosine.

PubMed Disclaimer

References

    1. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19(8):2201–2205 - DOI - PubMed
    1. Miyoshi A (1992) Clinical evaluation of Z-103 in the treatment of gastric ulcer: a multicenter double-blind dose finding study. Yakuri to chiryo 20(1):181–197
    1. Miyoshi A, Namiki A, Asagi S, Harasawa S, Ooshiba S, Hayakawa K (1992) Clinical evaluation of Z-103 on gastric ulcer–a multicenter double-blind comparative study with cetraxate hydrochloride. Jpn Pharm Ther 20:199–223
    1. Furuta S, Toyama S, Miwa M, Itabashi T, Sano H, Yoneta T (1995) Residence time of polaprezinc (zinc l-carnosine complex) in the rat stomach and adhesiveness to ulcerous sites. Jpn J Pharmacol 67(4):271–278 - DOI - PubMed
    1. Matsukura T, Tanaka H (2000) Applicability of zinc complex of L-carnosine for medical use. Biochemistry (Mosc) 65(7):817–823 - PubMed

Publication types

LinkOut - more resources